Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-03715455 inhaled twice daily in moderate to severe COPD
2014-002340-40Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PF-03715455 in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Pfizer. Primary endpoint: Change from baseline in trough FEV1 at Week 4. Started Aug 2014; status: terminated.
02
Drugs
PF-03715455
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2014-002340-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002340-40.